Renal Cancer

Antisense molecules can delay renal carcinoma growth in murine models

Published in Cancer Weekly, July 30th, 2002

by Sonia Nichols, senior medical writer - Molecules engineered for blocking the expression of vascular endothelial growth factor (VEGF) can restrict renal carcinoma growth in nude mice, researchers say.

VEGF is an important modulator of neovascularization, or angiogenesis in solid tumors. Cancer researchers have proposed that antisense oligonucleotides specifically targeting VEGF production could be used to diminish tumor vascularity. Researchers at the University of Florida in Gainesville report they have been able to significantly slow renal carcinoma tumor growth in nude mice by giving them systemic treatments of antisense oligonucleotides to VEGF.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-07-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry